Canaccord Genuity Group Reiterates “Buy” Rating for Diaceutics (LON:DXRX)

Diaceutics (LON:DXRX)‘s stock had its “buy” rating reaffirmed by equities researchers at Canaccord Genuity Group in a note issued to investors on Tuesday, Digital Look reports. They currently have a GBX 215 price objective on the stock. Canaccord Genuity Group’s target price points to a potential upside of 15.68% from the company’s previous close.

Diaceutics Stock Performance

Shares of Diaceutics stock opened at GBX 185.86 on Tuesday. The firm has a fifty day moving average of GBX 146.97 and a two-hundred day moving average of GBX 151.24. The company has a debt-to-equity ratio of 2.85, a quick ratio of 9.92 and a current ratio of 3.43. The stock has a market capitalization of £157.72 million, a price-to-earnings ratio of 1,689.61 and a beta of 0.88. Diaceutics has a 52 week low of GBX 125 and a 52 week high of GBX 191.

Diaceutics (LON:DXRX) last posted its quarterly earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share (EPS) for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. As a group, equities research analysts predict that Diaceutics will post 1.0107919 EPS for the current year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.